Bodybuilders Take Breast Cancer Drug

Tamoxifen, an endocrine therapy for women with breast cancer, is found in a supplement marketed to bodybuilders.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Tamoxifen pillsWIKIMEDIA, NCIFor decades, some bodybuilders who’ve taken steroids to help increase their muscle mass have illegally purchased the breast cancer drug tamoxifen to prevent breast enlargement. But according to new research from Liverpool John Moores University in the U.K., others may simply have bought the dietary supplement Esto Suppress, which was found to contain the drug in three out of four samples tested by the investigators, who published their results last week (February 13) as a letter in the British Medical Journal (BMJ).

“Since the 2000s, a growing number of off-the-shelf ‘food,’ ‘herbal,’ or ‘dietary’ ‘supplements’—aimed at gym goers and people wanting to lose weight or enhance their sex lives—have contained pharmacologically active substances,” the authors wrote. “Most users will be unaware that they are taking these substances.”

The amount of tamoxifen varied by sample, with one sample containing 3.8 mg per pill. The suggested dose of Esto Suppress is two pills per day; when the drug is prescribed for early-stage breast cancer, patients typically take 20 mg a day. The researchers noted, however, that their samples were purchased two years ago, and it is not known whether the supplement still contains tamoxifen.

“This research highlights the need for consumers to be aware when choosing their sports supplements,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies